NCT00518622View on ClinicalTrials.gov

Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Hepatitis C

Interventions

DRUG

Comparator: MK7009

Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.

DRUG

Comparator: Placebo

MK7009 Placebo

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00518622 - Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) | Biotech Hunter | Biotech Hunter